One of the characteristic features of aging is the progressive loss of muscle mass, a nosological syndrome called sarcopenia. It is also a pathologic risk factor for many clinically adverse outcomes in older adults. Therefore, delaying the loss of muscle mass, through either boosting muscle protein synthesis or slowing down muscle protein degradation using nutritional supplements could be a compelling strategy to address the needs of the world’s aging population. Here, we review the recently identified properties of docosahexaenoic acid (DHA). It was shown to delay muscle wasting by stimulating intermediate oxidative stress and inhibiting proteasomal degradation of muscle proteins. Both the ubiquitin–proteasome and the autophagy–lysosome systems are modulated by DHA. Collectively, growing evidence indicates that DHA is a potent pharmacological agent that could improve muscle homeostasis. Better understanding of cellular proteolytic systems associated with sarcopenia will allow us to identify novel therapeutic interventions, such as omega-3 polyunsaturated fatty acids, to treat this disease.
In tauopathic conditions, such as Alzheimer's disease (AD), highly soluble and natively unfolded tau polymerizes into an insoluble filament; however, the mechanistic details of this process are not clear. In AD brains, only a small segment of tau forms -helix-stacked protofilaments, while its flanking regions form disordered fuzzy coats. Here, we demonstrated that the tau AD nucleation core (tau-AC) sufficiently induced self-aggregation and recruited full-length tau to filaments. Unexpectedly, phospho-mimetic forms of tau-AC (at Ser324 or Ser356) showed markedly reduced aggregation and seeding propensities. Biophysical analysis revealed that the N-terminus of tau-AC facilitated the fibrillization kinetics, while its phosphorylation induced conformation changes, sterically shielding the nucleation motif. Tau-AC oligomers were efficiently internalized into cells via endocytosis and induced endogenous tau aggregation. In primary hippocampal neurons, tau-AC impaired axon initial segment plasticity upon chronic depolarization and was mislocalized in the somatodendritic compartments. Furthermore, we observed significantly impaired memory retrieval in mice intrahippocampally injected with tau-AC fibrils, which corresponded to the neuropathological staining and neuronal loss in the brain. These findings identified tau-AC species as a key neuropathological driver in AD, suggesting novel strategies for therapeutic intervention.